Ambrx Biopharma Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ambrx Biopharma Inc. (NASDAQ: AMAM) develops precision biologics using its proprietary synthetic biology-designed site-specific protein conjugation platform to create antibody drug conjugates and other targeted therapeutics for cancer and other diseases. The company offers ARX788, a next-generation HER2-targeting antibody drug conjugate in Phase 3 clinical trials for breast cancer; ARX517, a PSMA-targeting ADC in Phase 2 for metastatic castration-resistant prostate cancer; and ARX305, a CD70-targeting ADC in Phase 1, along with additional preclinical candidates leveraging its Dx3 site-specific conjugation technology for improved drug stability, efficacy, and safety profiles. Founded in 2010 and headquartered in Aliso Viejo, California, Ambrx operates primarily in the United States and China, with research and development facilities supporting its oncology-focused pipeline targeting solid tumors and hematologic malignancies for pharmaceutical partners and direct development. In recent major developments, Ambrx was acquired by Johnson & Johnson in 2024 for approximately $2 billion, integrating its ADC platform and lead candidates into J&J's Janssen Pharmaceutical Companies to accelerate global clinical programs and expand manufacturing capabilities. This transaction marked a strategic shift from standalone biopharma operations to a subsidiary role under J&J, with no reported name changes or reorganizations as of late 2025, while continuing pipeline advancement including ongoing collaborations with industry partners for conjugate technologies.
Ambrx Shareholders Approve Acquisition by Johnson & Johnson
3 Stocks to Buy That Are Up 200% or More in 2024
Is Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
Ambrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&J
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
Ambrx Biopharma stock doubles on JNJ deal
AMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to Shareholders
Ambrx Announces Sale to Johnson & Johnson
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer
The underdogs of 2023: Small-cap stocks that made it big
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
Ambrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO Data
Ambrx Biopharma: Potential With Recently Released Prostate Cancer Data
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments
Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress
Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023